Paper · 36930419
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
Nagahashi M and 22 others. Breast Cancer, 2023. Cited by 5 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients. Papers, record 36930419. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36930419
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA Copy Number Variations | Major topic |
| Triple Negative Breast Neoplasms | Major topic |
| Biomarkers, Tumor | Major topic |
| Humans | |
| Female | |
| Adult | |
| Middle Aged | |
| Aged | |
| Disease-Free Survival |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 22H03140 | Japan Society for the Promotion of Science | PubMed | ||
| 21K19522 | Japan Society for the Promotion of Science | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17,387,718 | Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. | Cancer | 2007 | https://conductscience.org/library/papers/17387718 | PubMed |
| 2 | 21,161,370 | Triple negative breast cancer: unmet medical needs. | Breast Cancer Res Treat | 2011 | https://conductscience.org/library/papers/21161370 | PubMed |
| 3 | 19,008,097 | What is triple-negative breast cancer? | Eur J Cancer | 2008 | https://conductscience.org/library/papers/19008097 | PubMed |
| 4 | 35,987,766 | Triple negative breast cancer: Pitfalls and progress. | NPJ Breast Cancer | 2022 | https://conductscience.org/library/papers/35987766 | PubMed |
| 5 | 24,657,537 | Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. | Curr Opin Genet Dev | 2014 | https://conductscience.org/library/papers/24657537 | PubMed |
| 6 | 27,498,871 | Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. | Cell Rep | 2016 | https://conductscience.org/library/papers/27498871 | PubMed |
| 7 | 28,061,528 | An ICGC major achievement in breast cancer: a comprehensive catalog of mutations and mutational signatures. | Chin Clin Oncol | 2017 | https://conductscience.org/library/papers/28061528 | PubMed |
| 8 | 30,853,353 | Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. | Cancer Cell | 2019 | https://conductscience.org/library/papers/30853353 | PubMed |
| 9 | 30,338,623 | Next generation sequencing-based gene panel tests for the management of solid tumors. | Cancer Sci | 2019 | https://conductscience.org/library/papers/30338623 | PubMed |
| 10 | 28,007,036 | Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. | Genome Med | 2016 | https://conductscience.org/library/papers/28007036 | PubMed |
1 to 10 of 37
See all 37 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,449,678 | Naturally Occurring Feline Cancers in Comparative Oncology: Translational Insights from Oral Squamous Cell Carcinoma and Mammary Carcinoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449678 | PubMed |
| 39,918,749 | The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition. | Ann Surg Oncol | 2025 | https://conductscience.org/library/papers/39918749 | PubMed |
| 38,542,328 | Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542328 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TP53 | 7,157 | PubTator's text mining | https://conductscience.org/library/genes/7157 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36930419
GET https://conductscience.org/api/papers/v1/36930419/authors?page=2